Statement re Sinclair Pharma announces a promotion and a new appointment

Sinclair Pharma plc announces the promotion of Paul Phull to Managing Director (Europe) & Executive VP and the appointment of Christophe Foucher as General Manager of CS Dermatologie 15 November 2007, Godalming, UK: Sinclair Pharma plc is pleased to announce the promotion of Paul Phull to Managing Director of Sinclair's European Sales and Marketing operations, and the appointment of Christophe Foucher as General Manager of Sinclair's French sales and marketing operation, CS Dermatologie (CSD). Mr Foucher will join Sinclair in January 2008. Mr Foucher comes to Sinclair from the dermatology company Galderma, where he has held several senior management positions, most recently General Manager, Italy. He joins the Sinclair Group as part of a succession plan to support the next period of operational growth. As part of this plan, Paul Phull will lead Sinclair's European sales and marketing operations. Didier Rase, current President and founder of CSD, will leave the Group to pursue other business interests. Mr Rase has made significant contributions to the integration of the Company into the Sinclair Group since its acquisition in April 2006. Mr Rase will contribute to a smooth handover process by remaining available until mid 2008. "The Sinclair Group has reached a critical point in its commercial development," said Paul Phull. "Our sales presence in five countries demands strategic, co-ordinated management so that Sinclair can derive the best returns on these investments and drive towards reaching critical mass in Europe. I look forward to delivering the best possible growth of the business." "I am delighted to be joining Sinclair at this important time for the business in France," said Christophe Foucher, "The role reflects my commercial experience in European dermatology very closely. The French business offers great potential for commercial development, not only within France but through synergies with our other territories." Paul Phull Mr Phull is an experienced executive in international pharmaceutical commercialisation, having worked in the healthcare industry for over 20 years. Mr Phull joined Sinclair in 2001 as Manager and then Director of Business Development, and in 2004 was appointed to the position of Executive Vice-President, Business Development with responsibility for Sinclair's global sales and business development via its marketing partners. Prior to joining Sinclair he held senior sales, marketing and business development positions at Bristol-Myers Squibb and Yamanouchi and has been involved in a number of biotech and healthcare start-up companies. As Managing Director, Europe, Mr Phull becomes responsible for all Sinclair's international commercial activities, including Sinclair's own operating companies in Europe and revenues through global marketing partners. Christophe Foucher Mr Foucher has 14 years experience in the pharmaceutical industry and joins Sinclair as General Manager of its French commercial operation. In his previous position at Galderma Laboratories he delivered annual double-digit sales growth over a four year period, gaining market leadership positions in the company's major territories. Reimbursement and management teams were a key strategic focus during this time. Christophe is currently the General Manager for Italy, prior to this he was the Regional Director for Middle Europe and worked in Sales & Marketing for 5 years, in Africa, Morocco and India. Christophe has a doctorate degree in pharmacy and a diploma in management studies. He is fluent in English, French and Italian, reflecting Sinclair's commercial presence in Europe. - ends - For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600 Dr Michael Flynn, CEO Jerry Randall, CFO Zoe McDougall, Director of Communications Capital MS&L Annabel O'Connor, Anna Mitchell Tel +44 (0)20 7307 5340 Notes to Editors: About Sinclair Pharma Plc Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors. ---END OF MESSAGE---